PU Conference Series: Euretina 2018

POWERFUL † TO IMPROVE PATIENTSʼ LIVES 1–6

† As measured by mean change in vrQoL. 1– 6

Lucentis ® – the only TGA-approved and PBS-listed anti-VEGF available in a pre-filled syringe. 7,8

NEW

nAMD

DME

BRVO CRVO

mCNV other CNV

BRVO, branch retinal vein occlusion; CNV, choroidal neovascularisation; CRVO, central retinal vein occlusion; DME, diabetic macular oedema; mCNV, myopic choroidal neovascularisation; nAMD, neovascular age-related macular degeneration; PBS, Pharmaceutical Benefits Scheme; TGA, Therapeutic Goods Administration; VEGF, vascular endothelial growth factor; vrQoL, vision-related quality of life.

PBS Information: Authority required for the treatment of wet AMD, DME, BRVO and CRVO. Refer to PBS Schedule for full Authority information. This product is not PBS listed for the treatment of CNV secondary to PM or to causes other than wet AMD. Before prescribing, please review PBS and product information available in the primary advertisement of this publication. References: 1. HernandoMet al. Eur J Hosp Pharm2018; 25 (Suppl 1): A129–A130. Poster 4CPS-187. 2. Turkoglu EB et al. J Diabetes Complications 2015; 29 (4): 540–543. 3. InoueMet al. ClinOphthalmol 2014; 8: 1711–1716. 4. Finger RP et al. Ophthalmology 2014; 121 (6): 1246–1251. 5. Symeonidis C et al. Ophthalmologica 2014; 232 (Suppl 2): 9. Abstract 169. 6. Charonis A et al. Ophthalmologica 2014; 232 (Suppl 2): 9. Abstract 165. 7. Lucentis ® Product Information. August 2017. 8. Pharmaceutical Benefits Scheme. Ranibizumab syringe. www.pbs.gov.au/medicine/item/10138N-10374B (accessed 16 May 2018). Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park, NSW 2113. ® Registered Trademark. AU-7315. McCann Health NOLU14800M/PUCS. September 2018.

POWERFUL. PRECISE. PROVEN.